These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21992960)

  • 1. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis.
    Martínez-Rodríguez JE; López-Botet M; Munteis E; Rio J; Roquer J; Montalban X; Comabella M
    Clin Immunol; 2011 Dec; 141(3):348-56. PubMed ID: 21992960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy.
    Martínez-Rodríguez JE; Saez-Borderías A; Munteis E; Romo N; Roquer J; López-Botet M
    Clin Immunol; 2010 Oct; 137(1):41-50. PubMed ID: 20580616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
    Sheridan JP; Zhang Y; Riester K; Tang MT; Efros L; Shi J; Harris J; Vexler V; Elkins JS
    Mult Scler; 2011 Dec; 17(12):1441-8. PubMed ID: 21807759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.
    Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR
    Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The regulatory role of natural killer cells in multiple sclerosis.
    Takahashi K; Aranami T; Endoh M; Miyake S; Yamamura T
    Brain; 2004 Sep; 127(Pt 9):1917-27. PubMed ID: 15229129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis.
    Vandenbark AA; Huan J; Agotsch M; La Tocha D; Goelz S; Offner H; Lanker S; Bourdette D
    J Neuroimmunol; 2009 Oct; 215(1-2):125-8. PubMed ID: 19758707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined low dose cyclosporine and prednisone down-regulate natural killer cell-like effector functions of CD8brightCD56+ T cells in patients with active Behçet uveitis.
    Ahn JK; Park YG; Park SW; Yoon KC; Yu HG; Chung H
    Ocul Immunol Inflamm; 2006 Oct; 14(5):267-75. PubMed ID: 17056460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment.
    Gonzalez VD; Falconer K; Björkström NK; Blom KG; Weiland O; Ljunggren HG; Alaeus A; Sandberg JK
    J Immunol; 2009 Nov; 183(10):6612-8. PubMed ID: 19846870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-related changes in natural killer cell receptors from childhood through old age.
    Almeida-Oliveira A; Smith-Carvalho M; Porto LC; Cardoso-Oliveira J; Ribeiro Ados S; Falcão RR; Abdelhay E; Bouzas LF; Thuler LC; Ornellas MH; Diamond HR
    Hum Immunol; 2011 Apr; 72(4):319-29. PubMed ID: 21262312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-β and interferon-β combined with low-dose oral steroids.
    Sanvito L; Tomita A; Chihara N; Okamoto T; Lin Y; Ogawa M; Gran B; Aranami T; Yamamura T
    J Neuroimmunol; 2011 Jul; 236(1-2):111-7. PubMed ID: 21652010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta.
    Saraste M; Irjala H; Airas L
    Neurol Sci; 2007 Jun; 28(3):121-6. PubMed ID: 17603762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells.
    Vitale M; Della Chiesa M; Carlomagno S; Romagnani C; Thiel A; Moretta L; Moretta A
    Eur J Immunol; 2004 Jun; 34(6):1715-22. PubMed ID: 15162442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation.
    Gigli G; Caielli S; Cutuli D; Falcone M
    Immunology; 2007 Nov; 122(3):409-17. PubMed ID: 17617156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human natural killer cell subsets and acute exercise: a brief review.
    Timmons BW; Cieslak T
    Exerc Immunol Rev; 2008; 14():8-23. PubMed ID: 19203081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8 T cells expressing killer Ig-like receptors and NKG2A are present in cord blood and express a more naïve phenotype than their counterparts in adult blood.
    Warren HS; Rana PM; Rieger DT; Hewitt KA; Dahlstrom JE; Kent AL
    J Leukoc Biol; 2006 Jun; 79(6):1252-9. PubMed ID: 16574769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.
    Johnson TA; Evans BL; Durafourt BA; Blain M; Lapierre Y; Bar-Or A; Antel JP
    J Immunol; 2011 Jul; 187(1):570-9. PubMed ID: 21622858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry.
    Ranganath T; Simpson LJ; Ferreira AM; Seiler C; Vendrame E; Zhao N; Fontenot JD; Holmes S; Blish CA
    Front Immunol; 2020; 11():714. PubMed ID: 32391016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased proportion of the CD56(bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy.
    Lee S; Watson MW; Flexman JP; Cheng W; Hammond T; Price P
    J Med Virol; 2010 Apr; 82(4):568-74. PubMed ID: 20166183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implication of the Toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis.
    Bustamante MF; Fissolo N; Río J; Espejo C; Costa C; Mansilla MJ; Lizasoain I; Moro MA; Carmen Edo M; Montalban X; Comabella M
    Ann Neurol; 2011 Oct; 70(4):634-45. PubMed ID: 22028223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
    Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
    Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.